John Leonard, Intellia CEO

Bask­ing in lime­light of a CRISPR break­through, In­tel­lia bags $600M cash raise as shares soar to all-time high

“Raise mon­ey when you can, not when you have to” has be­come a fa­mil­iar re­frain in the biotech world. On the heels of a land­mark break­through for in vi­vo CRISPR/Cas9 edit­ing, In­tel­lia Ther­a­peu­tics is cer­tain­ly tak­ing it to heart.

The gene edit­ing pi­o­neer has loaded up in a new pub­lic of­fer­ing that sold its shares at $145 a pop — a 60% jump from its clos­ing price on Fri­day, just ahead of an in­dus­try-shak­ing mile­stone. Over the week­end, it dropped ini­tial da­ta sug­gest­ing that it can use CRISPR to di­rect­ly ed­it DNA in hu­mans, of­fer­ing a land­mark proof-of-con­cept for the bur­geon­ing field.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Venture & Research Associate

Alexandria Real Estate Equities

San Francisco, CA, USA